Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
GSK-3536819 (MenABCWY) is a novel combination meningococcal vaccine developed by GSK to provide protection against Neisseria meningitidis serogroups A, B, C, W, and Y. This pentavalent formulation merges the immunological benefits of existing MenB and MenACWY vaccines into one comprehensive solution. Ideal for preteens, adolescents, and young adults, the MenABCWY GSK vaccine helps reduce complexity in vaccine administration and enhances compliance with CDC meningococcal vaccination guidelines. For clinics and immunization providers looking to buy MenABCWY, this product offers a clinically efficient alternative to separate MenB and MenACWY vaccinations.
| Fact Table | |
|---|---|
| Formula | Not applicable (vaccine – biologic formulation) |
| License | FDA approved (October 2023) |
| Bioavailability | Not applicable (intramuscular injection) |
| Legal status | Prescription only (Rx) |
| Chemical Name | Meningococcal Group A, C, W, Y and B Vaccine |
| Elimination half-life | Not applicable |
| Dosage (Strength) | Single-dose injection (0.5 mL) |
| Pregnancy | Consult healthcare provider |
| Brands | Penbraya |
| Protein binding | Not applicable |
| PubChem CID | Not listed |
| MedlinePlus | Not assigned |
| ChEBI | Not available |
| ATC code | J07AH10 |
| DrugBank | Not assigned |
| KEGG | Not available |
| Routes of administration | Intramuscular injection |
Administered as a two-dose intramuscular series, the MenABCWY vaccine is injected into the upper arm (deltoid muscle), with the second dose given six months after the first. It is crucial to complete the series within the recommended interval to ensure optimal immune protection against all covered serogroups. Healthcare providers must follow established immunization schedules and maintain accurate patient records.
Each MenABCWY dose contains polysaccharide antigens from meningococcal serogroups A, C, W, and Y conjugated to CRM197, in addition to recombinant protein antigens targeting serogroup B. The formulation includes aluminum hydroxide as an adjuvant and uses a histidine buffer system with sodium chloride and sterile water. The vaccine is free from preservatives and latex.
MenABCWY GSK should be administered with caution to individuals with a history of severe allergic reactions, neurological conditions such as Guillain-Barré Syndrome, or those with compromised immune responses. Patients experiencing an acute illness or fever should delay vaccination. For providers aiming to buy MenABCWY for distribution or public health campaigns, thorough screening of patient history is essential for safety and efficacy.
MenABCWY is contraindicated in individuals who have demonstrated hypersensitivity to vaccine components or any prior meningococcal vaccine containing similar antigens. A severe allergic reaction to diphtheria toxoid or CRM197 also warrants exclusion from administration.
Reported side effects include:
These effects are typically transient and self-limiting. Rare but serious reactions should be reported through established vaccine safety monitoring systems.
What is the MenABCWY (GSK-3536819) vaccine?
MenABCWY is a vaccine that provides protection against five major serogroups of meningococcal bacteria (A, B, C, W, and Y) in a single injection.
Who should receive the MenABCWY vaccine?
The vaccine is recommended for adolescents and young adults, particularly those entering college, living in dormitories, or with certain medical conditions that increase risk of meningococcal disease.
What diseases does MenABCWY prevent?
It helps prevent meningococcal meningitis and septicemia (bloodstream infection), which can cause serious illness and death within hours if left untreated.
How is the MenABCWY vaccine administered?
It's given as a single intramuscular injection, typically in the upper arm or thigh.
What are common side effects of the MenABCWY vaccine?
Common side effects include pain/redness at the injection site, headache, fatigue, muscle pain, and mild fever, which typically resolve within a few days.
How long does protection from MenABCWY last?
Protection typically lasts several years, though exact duration may vary. Healthcare providers may recommend boosters based on risk factors.
Can MenABCWY be given at the same time as other vaccines?
Yes, it can generally be administered during the same visit as other age-appropriate vaccines, though they should be given at different injection sites.
Is MenABCWY different from previous meningococcal vaccines?
Yes, it's the first single vaccine to protect against all five major disease-causing meningococcal serogroups (previous vaccines covered either serogroup B or serogroups A, C, W, and Y).
Are there any contraindications for receiving MenABCWY?
The vaccine shouldn't be given to individuals with severe allergic reactions to any component of the vaccine or to those who had a severe reaction to a previous dose.
When will MenABCWY be widely available?
Following clinical trials and regulatory approvals, the vaccine is expected to be available through healthcare providers after receiving final authorization from regulatory agencies.
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews